Open Journal Systems

Multi-organ dysfunction in Sickle Cell Disease: a rare presentation and its management in resource-limited setting.

Fatma A Bakshi, Semvua B Kilonzo, Daniel W Gunda, Elichilia R Shao

Abstract


Introduction: Chronic end-organ damage among the sicklers is frequently diagnosed in Tanzania, but rarely involves multiple organs in a single patient.

Case report: A 26-year-old Tanzanian black-sickler woman presented with features related to avascular necrosis of the right hip, left ventricular hypertrophy, pulmonary hypertension, Chronic Kidney Disease and Cholelithiasis. Despite the management given, her condition is still deteriorating.

Conclusion: Prevention of these complications through screening and early diagnosis with a concurrent timely treatment should be advocated by all health-care providers

Keywords


Sickle cell disease, avascular necrosis, LV hypertrophy, pulmonary hypertension, chronic kidney disease, cholelithiasis

Full Text:

PDF

References


van-Beers EJ, van Tuijn CFJ, Mac-Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008; 93(5):757–60.

Hiran S. Multiorgan dysfunction syndrome in sickle cell disease. J Assoc Physicians India 2005;53:19–22.

Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep 2006;128(2):110–6.

Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85(1):6–13.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312(10):1033–48.

Vaishya R, Agarwal AK, Edomwonyi EO, et al. Musculoskeletal Manifestations of Sickle Cell Disease: A Review. Curēus 1989; 7(10):e358.

Jawad MU, Haleem AA, Scully SP. In brief: Ficat classification: avascular necrosis of the femoral head. Clin Orthop Relat Res. 2012; 470 (9):2636–9.

Kato GJ, Sachdev V. Diastolic dysfunction in sickle cell. Blood 2010;116(1):1–2.

De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008; 83(1):19–25.

Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350(9):886–95.

Saxena AK, Panhotra BR, Al-Arabi Al et al. End-Stage Sickle Cell Nephropathy: determinants of Reduced Survival of Patients on Long-term Hemodialysis. Saudi J Kidney Dis Transpl 2013;15(2):174–5.

Nielsen L, Canouï-Poitrine F, Jais J-P, et al. Morbidity and mortality of sickle cell disease patients starting intermittent hemodialysis: a comparative cohort study with non- Sickle dialysis patients. Br J Haematol 2016; 174(1):148-52.

Gumiero AP dos S, Bellomo-Brandão MA, et al. Gallstones in children with sickle cell disease followed up at a Brazilian hematology center. Arq Gastroenterol 2013;45(4):313–8.

Giuseppe C, Meo AS, Ippolito-Daniella IK, et al. Asymptomatic Cholelithiasis in Children With Sickle Cell Disease: Early or Delayed Cholecystectomy? Ann Surg 2007; 245(1): 126–129.




DOI: https://doi.org/10.4314/tmj.v29i1.266

DOI (PDF): https://doi.org/10.4314/tmj.v29i1.266.g139

Refbacks

  • There are currently no refbacks.
x
Message